Regenerative Medicine Institute (REMEDI), National Centre for Biomedical Engineering Science (NCBES), National University Ireland Galway (NUIG), Galway, Ireland.
Curr Diab Rep. 2014 Mar;14(3):469. doi: 10.1007/s11892-013-0469-6.
Cell therapy has enormous potential for the treatment of conditions of unmet medical need. Cell therapy may be applied to diabetes mellitus in the context of beta cell replacement or for the treatment of diabetic complications. A large number of cell types including hematopoietic stem cells, mesenchymal stem cells, umbilical cord blood, conditioned lymphocytes, mononuclear cells, or a combination of these cells have been shown to be safe and feasible for the treatment of patients with diabetes mellitus. The first part of this review article will focus on the current perspective of the role of embryonic stem cells and inducible pluripotent stem cells for beta cell replacement and the current clinical data on cell-based therapy for the restoration of normoglycemia. The second part of this review will highlight the therapeutic role of MSCs in islet cells cotransplantation and the management of diabetes related vascular complications.
细胞治疗在治疗未满足的医疗需求的疾病方面具有巨大的潜力。细胞治疗可应用于糖尿病的β细胞替代治疗，或用于治疗糖尿病的并发症。大量细胞类型，包括造血干细胞、间充质干细胞、脐带血、条件性淋巴细胞、单核细胞，或这些细胞的组合，已被证明在治疗糖尿病患者方面是安全可行的。本文综述的第一部分将重点介绍胚胎干细胞和诱导多能干细胞在β细胞替代中的作用，以及基于细胞治疗恢复正常血糖的最新临床数据。本文综述的第二部分将重点介绍间充质干细胞在胰岛细胞共移植和糖尿病相关血管并发症管理中的治疗作用。
